Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abingdon HealthABDXF 53 Net Cash per Share is $0.00 as of Dec. 2025. GuruFocus rates ABDXF with a GF Score™ of 53/100 and a GF Value™ of $0.15 (Fairly Valued). The stock has 7 warning signs investors should review. Among 59 Medical Diagnostics & Research companies, Abingdon Health ranks worse than 1694913.56% on this metric.
The historical rank and industry rank for Abingdon Health's Net Cash per Share or its related term are showing as below:
During the past 8 years, the highest Price-to-Net-Cash Ratio of Abingdon Health was 15.70. The lowest was 6.50. And the median was 11.10.
ABDXF's Price-to-Net-Cash is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 8.29 * Ranked among companies with meaningful Price-to-Net-Cash only.
Abingdon Health (OTCPK:ABDXF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Abingdon Health Net Cash per Share Related Terms
Abingdon Health Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Abingdon Health's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABDXF vs TMO, DHR, IDXX: Net Cash per Share Comparison
For the Diagnostics & Research subindustry, Abingdon Health's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health Price-to-Net-Cash vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Abingdon Health's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Abingdon Health's Net Cash per Share for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abingdon Health (ABDXF) has a Net Cash per Share of $0.00 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Abingdon Health and its competitors. Over the past decade, Abingdon Health's Net Cash per Share has ranged from 6.50 to 15.70. According to the industry distribution chart, Abingdon Health ranks #999999 out of 59 companies in the Medical Diagnostics & Research industry.
Is Abingdon Health's Net Cash per Share too high?
Abingdon Health's current Net Cash per Share is $0.00. Over the past 10 years, this metric has ranged from a low of 6.50 to a high of 15.70. Based on the distribution chart, Abingdon Health ranks #999999 out of 59 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Abingdon Health has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's Net Cash per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Abingdon Health ranks #999999 out of 59 companies for Net Cash per Share. This places Abingdon Health in the lower half of its industry. The industry median Net Cash per Share is 8.29. Historically, Abingdon Health's own Net Cash per Share has ranged from 6.50 to 15.70 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Diagnostics & Research company?
The median Net Cash per Share among Medical Diagnostics & Research companies is 8.29, based on 59 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Abingdon Health and its competitors. For the Medical Diagnostics & Research industry, the median Net Cash per Share is 8.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abingdon Health's current Net Cash per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Fairly Valued. The stock's GF Value™ is $0.15, compared to a current price of $0.14 — trading 6% below its estimated fair value. The current Net Cash per Share is $0.00. Abingdon Health's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current Net Cash per Share is $0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abingdon Health (ABDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued.
The current stock price of $0.14 is trading 6% below its estimated GF Value™ of $0.15.
GuruFocus considers Abingdon Health to be Fairly Valued.
Key valuation signals for ABDXF:
Net Cash per Share: $0.00
GF Value™: $0.15 vs. price of $0.14 (6% below fair value)
No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
53GF Score
Get the complete analysis for ABDXF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABDXF has been successfully added to your 
